Deep Mutational Scanning to Predict Escape from Bebtelovimab in SARS-CoV-2 Omicron Subvariants

The major concern with COVID-19 therapeutic monoclonal antibodies is the loss of efficacy against continuously emerging variants of SARS-CoV-2. To predict antibody efficacy against future Omicron subvariants, we conducted deep mutational scanning (DMS) encompassing all single mutations of the receptor-binding domain of the BA.2 strain utilizing an inverted infection assay with an ACE2-harboring virus and library spike-expressing cells. In the case of bebtelovimab, which preserves neutralization activity against BA.2 and BA.5, a broad range of amino acid substitutions at K444, V445, and G446, and some substitutions at P499 and T500, were indicated to achieve the antibody escape. Among subvariants with current rises in case numbers, BA2.75 with G446S partially evaded neutralization by bebtelovimab, while complete evasion was observed in XBB with V445P and BQ.1 with K444T. This is consistent with the DMS results against BA.2, highlighting the potential of DMS as a predictive tool for antibody escape.

[1]  C. Wong Subvariant ‘soup’ may drive wave , 2022, New Scientist.

[2]  J. Zahradník,et al.  Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant , 2022, Cell Host & Microbe.

[3]  A. Walls,et al.  Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domains , 2022, bioRxiv.

[4]  Fei Shao,et al.  BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection , 2022, Nature.

[5]  Jumpei Ito,et al.  Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies , 2022, The Lancet Infectious Diseases.

[6]  K. Katoh,et al.  An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo , 2022, Science Translational Medicine.

[7]  J. Dye,et al.  LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants , 2022, Cell Reports.

[8]  Shinji Watanabe,et al.  Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2 , 2022, The New England journal of medicine.

[9]  D. Fremont,et al.  An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies , 2022, Nature Medicine.

[10]  P. Maes,et al.  Considerable escape of SARS-CoV-2 Omicron to antibody neutralization , 2021, Nature.

[11]  P. Pang,et al.  Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. , 2021, The New England journal of medicine.

[12]  J. Takagi,et al.  Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2 , 2021, Nature Communications.

[13]  L. Purcell,et al.  Tackling COVID-19 with neutralizing monoclonal antibodies , 2021, Cell.

[14]  E. Procko,et al.  An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants , 2021, Science Advances.

[15]  J. Bloom,et al.  Prospective mapping of viral mutations that escape antibodies used to treat COVID-19 , 2021, Science.

[16]  D. Skovronsky,et al.  SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 , 2020, The New England journal of medicine.

[17]  G. Atwal,et al.  REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters , 2020, Science.

[18]  Sarah K. Hilton,et al.  Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding , 2020, Cell.

[19]  Caitlyn E. Bowman,et al.  The ATP/ADP translocase drives mitophagy independent of nucleotide exchange , 2019, Nature.

[20]  Trevor Bedford,et al.  Deep mutational scanning of hemagglutinin helps predict evolutionary fates of human H3N2 influenza variants , 2018, Proceedings of the National Academy of Sciences.

[21]  Sarah K. Hilton,et al.  Mapping mutational effects along the evolutionary landscape of HIV envelope , 2017, bioRxiv.

[22]  H. Schwalbe,et al.  Retroviral Vectors Pseudotyped with Severe Acute Respiratory Syndrome Coronavirus S Protein , 2004, Journal of Virology.